Meteor Biotech installs spatial biology platform, CosmoSort, at Magnify, CNSI incubator on UCLA campus

Synergy between Meteor Biotech’s spatial cell sorting technology and Magnify’s startup accelerator resources will facilitate impactful therapeutic advancements in oncology, neurology and immunology

Seoul, South Korea, August 26, 2025 – Meteor Biotech, a specialized spatial omics technology company producing region-targeted cell sorting devices for advanced biomedical research, today announces the installation of its new generation spatial biology platform, CosmoSort, at Magnify, the California NanoSystems Institute (CNSI) incubator site, and location of Meteor Biotech’s newly created US office. Centrally located on UCLA’s (University of California, Los Angeles) campus, Magnify provides high-quality, affordable facilities, services and expertise within a vibrant innovation community, to accelerate the growth and success of transformative technology startups. 

With its spatial cell sorter equipment now installed at Magnify, Meteor Biotech can begin welcoming researchers and drug developers in oncology, neurology, immunology and biomarker discovery from across the US, to access the company’s proprietary Spatially-Resolved Laser-Activated Cell Sorting (SLACS) technology.

SLACS enables researchers to physically isolate and extract specific cells from tissue sections with exceptional speed and accuracy, allowing for deeper and more detailed single-cell analysis. This goes far beyond conventional spatial omics platforms focusing on charting expression profiles, throughout tissue specimens.

“Meteor Biotech is thrilled to establish our new office at the Magnify Incubator. This milestone marks a significant step forward in the growth of our company, while underscoring our commitment to fostering innovation and collaboration within the vibrant ecosystem of CNSI,” said Dr. Amos Lee, co-founder and CEO of Meteor Biotech. “By installing CosmoSort, we are enabling researchers to conduct single-cell analysis at an unprecedented level; we anticipate that this will accelerate groundbreaking discoveries. The synergy between our mission and the incubator’s vision of accelerating transformative technology startups makes this partnership a perfect fit.”

Academic scientists and drug developers will be able to use CosmoSort to conduct hands-on trials, demonstrations and pilot studies. Meteor Biotech will also offer on-site trials and customer training.

“Magnify, the CNSI incubator, is excited to welcome Meteor Biotech. The company’s decision to install its new office and make cutting-edge scientific equipment available here is a testament to the collaborative and innovative environment we strive to create,” said Nikki Lin, director of the Magnify Incubator at CNSI. “By providing researchers with access to advanced bioresearch analysis tools, Meteor Biotech is not only enhancing our ecosystem but also contributing to the broader scientific community. Together, we look forward to driving impactful advances in biotechnology and fostering a culture of innovation and excellence.”

About Magnify 

Centrally located at UCLA’s Court of Sciences, Magnify strives to enhance the vibrant culture of entrepreneurship at UCLA and the broader Los Angeles region. Featuring flexible co-working laboratory and office spaces, Magnify was built with one goal in mind: to help startups succeed by vastly accelerating their access to facilities while increasing their capital efficiency and market opportunities.

www.magnify.cnsi.ucla.edu  

About Meteor Biotech

Meteor Biotech is a specialized spatial omics technology company producing region-targeted cell sorting devices for advanced bioresearch analysis, including genomics, transcriptomics and proteomics. A spin-off from Seoul National University and leveraging over a decade of research and engineering, Meteor has developed its proprietary platform technology, SLACS (Spatially-Resolved Laser-Activated Cell Sorting), with which it has pioneered the world’s first spatial cell sorter, CosmoSort. CosmoSort enables researchers to sort specific regions of interest from tissue sections with high spatial precision, supporting a wide range of applications in cancer biology, immunology and neuroscience, among others. By empowering scientists to both observe and retrieve spatially defined cells, CosmoSort transforms static imaging into dynamic discovery — enabling researchers to translate spatial insights into deeper, more actionable, biological understanding.

Founded in 2022, Meteor Biotech has raised over $60M in funding, predominantly in grants. The company, headquartered in South Korea, with a new office in the US, currently commercializes CosmoSort, its award-winning device, in Asia and North America, with plans to expand into Europe.

www.meteorbiotech.com